Correlation between serum gastrin and cellular proliferation in Barrett's esophagus

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 2, 2011, Pages 89-94

  Green, Daniel A ^a   Abrams, Julian A ^b   Vaccaro, Benjamin J ^a   Capiak, Kristina M ^a   Quante, Michael ^a   Lightdale, Charles J ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Barrett's esophagus; Cellular proliferation; Esophageal cancer; Gastrin

Indexed keywords

ACETYLSALICYLIC ACID; GASTRIN; KI 67 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIET RESTRICTION; ESOPHAGUS BIOPSY; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SEX; TREATMENT DURATION;

EID: 79953316196     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X10392444     Document Type: Article

References (24)

1. Binato M. Gurski R.R. Fagundes R.B. Meurer L. Edelweiss M.I. (2009) P53 and Ki-67 overexpression in gastroesophageal reflux disease–Barrett's esophagus and adenocarcinoma sequence. Dis Esophagus 22: 588–595.
2. Conio M. Filiberti R. Blanchi S. Ferraris R. Marchi S. Ravelli P. et al (2002) Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 97: 225–229.
3. Feith M. Stein H.J. Mueller J. Siewert J.R. (2004) Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 17: 322–327.
4. Ferrand A. Wang T.C. (2006) Gastrin and cancer: a review. Cancer Lett 238: 15–29.
5. Fox J.G. Wang T.C. Rogers A.B. Poutahidis T. Ge Z. Taylor N. et al (2003) Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology 124: 1879–1890.
6. Georgopoulos S.D. Polymeros D. Triantafyllou K. Spiliadi C. Mentis A. Karamanolis D.G. et al (2006) Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 74: 42–46.
7. Gerdes J. Lemke H. Baisch H. Wacker H.H. Schwab U. Stein H. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715.
8. Grabowska A.M. Watson S.A. (2007) Role of gastrin peptides in carcinogenesis. Cancer Lett 257: 1–15.
9. Guzinska-Ustymowicz K. Pryczynicz A. Kemona A. Czyzewska J. (2009) Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res 29: 3049–3052.
10. Haigh C.R. Attwood S.E. Thompson D.G. Jankowski J.A. Kirton C.M. Pritchard D.M. et al (2003) Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK 2 receptor. Gastroenterology 124: 615–625.
11. Harris J.C. Clarke P.A. Awan A. Jankowski J. Watson S.A. (2004) An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 64: 1915–1919.
12. Jansen J.B. Klinkenberg-Knol E.C. Meuwissen S.G. de Bruijne J.W. Festen H.P. Snel P. et al (1990) Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99: 621–628.
13. Koop H. Klein M. Arnold R. (1990) Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 4: 131–138.
14. Lagergren J. Bergstrom R. Lindgren A. Nyren O. (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825–831.
15. Lieberman D.A. Oehlke M. Helfand M. (1997) Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 92: 1293–1297.
16. Nemeth J. Varro A. Bridson J. Walker R. Dockray G.J. (1992) Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole. Eur J Clin Invest 22: 638–644.
17. Polkowski W. van Lanschot J.J. Ten Kate F.J. Baak J.P. Tytgat G.N. Obertop H. et al (1995) The value of p 53 and Ki 67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 4: 163–171.
18. Rioux-Leclercq N. Turlin B. Sutherland F. Heresbach N. Launois B. Campion J.P. et al (1999) Analysis of Ki-67, p 53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus. Oncol Rep 6: 877–882.
19. Shaheen N. Ransohoff D.F. (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287: 1972–1981.
20. Sikkema M. Kerkhof M. Steyerberg E.W. Kusters J.G. van Strien P.M. Looman C.W. et al (2009) Aneuploidy and overexpression of Ki 67 and p 53 as markers for neoplastic progression in Barrett's esophagus: a case–control study. Am J Gastroenterol 104: 2673–2680.
21. Thorburn C.M. Friedman G.D. Dickinson C.J. Vogelman J.H. Orentreich N. Parsonnet J. (1998) Gastrin and colorectal cancer: a prospective study. Gastroenterology 115: 275–280.
22. Wang J.S. Varro A. Lightdale C.J. Lertkowit N. Slack K.N. Fingerhood M.L. et al (2010) Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 105: 1039–1045.
23. Wang K.K. Sampliner R.E. (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103: 788–797.
24. Wang T.C. Dangler C.A. Chen D. Goldenring J.R. Koh T. Raychowdhury R. et al (2000) Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118: 36–47.